TICKERNERD
Menu
KRSAKRSAHealthcare · Biotechnology

KRSA Stock Forecast: Korsana Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$32
+29.91% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$0.00
Ticker Nerd rank
42 / 100
Median analyst target
$8.00
Analysts covering
0
Revenue$0.0−100.0% y/y
Operating income−$1.8M
Net income−$1.8M
Free cash flow−$1.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.1%
1M
+27.7%
YTD
+258.9%
1Y
+78.7%
From 52W high
−28.6%
From 52W low
+322.0%
$8
$45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KRSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Korsana Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Accruals
78
Momentum
65
Value
54
Revisions
44
Issuance
33
Quality
30
Volatility
19
Growth
18

Size (88): Smaller than most of the companies we track.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KRSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KRSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26KRSAHigh $8.00Median $8.00Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Sept 2026UBSInitiatesBuy$55
20 Oct 2021Truist SecuritiesInitiatesBuy$14
24 Sept 2021Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KRSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Korsana Biosciences, Inc. returned +78.7% against +17.5% for the S&P 500, dividends included.

KRSA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Oct 25Jan 26Apr 26Jul 26KRSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KRSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Korsana Biosciences, Inc. (KRSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 87% of US stocks

Price / sales
8.7×

Cheaper than 16% of US stocks

Price / book
2.9×

Cheaper than 33% of US stocks

EV / EBITDA
0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
104.9%

Higher than 96% of US stocks

Return on assets
−23.1%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Korsana Biosciences, Inc. (KRSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Korsana Biosciences, Inc. has a market value of $0.0 and an enterprise value of $0.0.

  • Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$6.7M, a −353.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$4.5M.

  • Shares outstanding: 4.3M.

  • Trailing P/E: −3.1×; forward P/E: −18.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Korsana Biosciences, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

KRSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KRSAKorsana Biosciences, Inc.$0.00
42
TCRXTScan Therapeutics, Inc.$20.9M
51
LTRNLantern Pharma, Inc.$21.8M
54
CLRBCellectar Biosciences, Inc.$21.8M
27
JSPRJasper Therapeutics, Inc.$22.0M
41
PBMPsyence Biomedical Ltd.$20.6M
4
GRDXGridAI Technologies Corp.$20.3M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Korsana Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KRSA news & analysis

Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

GlobeNewsWire · 8 Sept 2026positive

Korsana Biosciences completed the closing of its previously announced merger with Cyclerion Therapeutics, alongside a private placement of $380 million. The combined company will advance lead program KRSA-028, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or the first quarter of 2028.

Why it matters — The completed merger and substantial private placement recapitalize the company and fund the advancement of its lead Alzheimer's program KRSA-028 toward the clinic.

FAQ

Frequently asked questions about KRSA stock

How does Ticker Nerd's model rank KRSA?

As at 12 Sept 2026, Korsana Biosciences, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

What is the KRSA stock forecast for 2030?

No analyst covering Korsana Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $8 over the next 12 months.

How has KRSA stock performed over the past year?

Korsana Biosciences, Inc. returned +78.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Korsana Biosciences, Inc. do?

Korsana Biosciences, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with an initial emphasis on Alzheimer’s disease.

What is the latest news on KRSA?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million". Korsana Biosciences completed the closing of its previously announced merger with Cyclerion Therapeutics, alongside a private placement of $380 million. The combined company will advance lead program KRSA-028, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or the first quarter of 2028.

Company

About Korsana Biosciences, Inc.

Korsana Biosciences, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with an initial emphasis on Alzheimer’s disease. Its work centers on THETA, a proprietary blood-brain barrier shuttle platform designed to improve delivery of large therapeutic molecules into the central nervous system. The company’s current pipeline includes THETA-enabled antibody programs aimed at addressing disease biology in the brain, including an anti-amyloid beta approach for Alzheimer’s disease. Korsana Biosciences operates in the health care and life sciences sector, where its role is to advance precision-engineered biologics for central nervous system disorders. The company is based in Waltham, Massachusetts.

CEO Dr. Jonathan Violin M.B.A., Ph.D. · United States · https://korsana.com